CHRONIC LYMPHOCYTIC LEUKEMIA

This study tests a new COVID-19 booster vaccine (GEO-CM04S1) in 80 people with chronic lymphocytic leukemia (CLL), whose immune systems often don't respond well to standard vaccines. The new vaccine uses a modified virus to better activate T cells, which are key infection-fightin…

This study tests whether giving two pneumonia vaccines (PCV20 and PPSV23) in a series can help people with chronic lymphocytic leukemia (CLL) build a stronger immune defense against pneumococcal infections. About 61 participants with CLL who have not had treatment or are on a spe…

This early-phase study tests azer-cel, a ready-made CAR T cell therapy, in adults with non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia that has come back or stopped responding to treatment. The goal is to check safety and how well the therapy works. About 135 particip…

This study is for people with certain blood cancers (like CLL or lymphoma) who are starting a type of targeted drug called a BTK inhibitor. These drugs can raise blood pressure and increase the risk of heart problems. The study will test whether carefully managing any new or wors…

This early-stage study tests an experimental drug called CC312 in about 44 adults with certain blood cancers (like lymphoma or leukemia) that have returned or stopped responding to standard treatments. The main goals are to check the drug's safety and find the best dose. Research…

This early-phase study tests a new type of immunotherapy for people with advanced B-cell lymphoma or leukemia that has returned or not responded to standard treatment. Researchers take a patient's own T-cells (a type of immune cell), add a special receptor that targets a protein …

This study looks at how to safely start a combination of drugs (venetoclax plus obinutuzumab or acalabrutinib) in people with untreated chronic lymphocytic leukemia (CLL). The main goal is to find the best way to increase the dose of venetoclax over time to reduce the risk of a s…

This study tests whether adding obinutuzumab to acalabrutinib works better than acalabrutinib alone for people with early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are at high risk of their disease getting worse. About 120 adults will receiv…

This study tests whether adding the drug epcoritamab after standard treatment can help people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) achieve a deeper remission. About 22 adults who have already received at least 12 months of a BTK inhibitor (a…

This study tests a combination of three drugs (acalabrutinib, venetoclax, and durvalumab) in people with Richter transformation, a rare and fast-growing lymphoma that can develop from chronic lymphocytic leukemia (CLL). The goal is to see if this treatment can improve survival by…

This study tests whether the drug mosunetuzumab, given alone or with a BTK inhibitor (like ibrutinib), can clear tiny amounts of leftover leukemia cells in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 40 adults who are already on or ha…

This study tests a new drug, BGB-16673, against standard treatments (like idelalisib plus rituximab or bendamustine plus rituximab) in 250 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already been treated with both BTK and BCL2 inhib…

This study tests an oral drug called AS-1763 in about 120 adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas. Participants must have tried at least two prior treatments without success or had side effects. The main goals ar…

This study tests whether adding a new drug called roginolisib to two standard drugs (venetoclax and rituximab) is safe and works better for people with chronic lymphocytic leukemia (CLL) that has come back or not responded to prior treatments. About 64 adults who have already tri…

This study tests a one-year treatment plan using two drugs, pirtobrutinib and obinutuzumab, for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if this fixed-duration therapy can effectively control the disease with…

This study tests a new drug called BGB-16673 in 150 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer came back or stopped responding to previous BTK inhibitor pills. Participants are randomly assigned to get BGB-16673 or one of two s…

This study tests a new drug called APG-2575 in people whose chronic lymphocytic leukemia or small lymphocytic lymphoma has come back or stopped responding to other treatments. About 75 adults will take the drug alone to see if it shrinks tumors and how safe it is. The goal is to …

This study follows 705 adults with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma who are taking zanubrutinib. Researchers want to see how the drug affects quality of life and how often patients need hospital care. Th…

This study tests two drug combinations (acalabrutinib plus venetoclax or obinutuzumab) in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see if these combinations can shrink tumors and achieve very low levels of cancer cells…

This study tests whether taking nicotinamide (a form of vitamin B3) twice daily can lower the risk of new non-melanoma skin cancers in people with chronic lymphocytic leukemia (CLL) who have already had at least one skin cancer. About 86 participants will be randomly assigned to …

This study uses a cord blood transplant after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. About 200 participants will receive the transplant to see if it improves survival one year later. The approach aims to replace diseased bone …

This study tests a new kind of CAR T-cell therapy for adults with certain blood cancers (B-cell lymphoma or chronic lymphocytic leukemia) that have come back or not responded to treatment. The therapy uses a patient's own immune cells that are specially modified to be more energe…

This study tests whether a combination of three drugs (zanubrutinib, obinutuzumab, and sonrotoclax) can make cancer cells undetectable in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 40 adults who need treatment for the first…

This study tests whether combining two targeted drugs, pirtobrutinib and venetoclax, can eliminate cancer cells in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose disease got worse despite taking standard BTK inhibitors. About 30 adults wh…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) who were already in a previous trial. About 279 participants will continue their treatment or follow-up visits. The main goal is to t…

This study tests whether a faster dose increase of the drug sonrotoclax, given with other medicines, is safe for people with certain blood cancers (CLL, SLL, or mantle cell lymphoma). The cancers may be new, returned, or not responding to treatment. The goal is to see if this qui…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already been treated with a BTK inhibitor. It is open to 150 participants who completed a previous related study. Part…

This study tests a two-step, lower-intensity approach using radiation and chemotherapy before a stem cell transplant for people with various blood cancers or disorders. The goal is to see if this gentler preparation reduces the risk of death from the transplant itself. About 63 p…

This study tests a new drug, sonrotoclax, combined with antibody therapy for adults with relapsed or hard-to-treat chronic lymphocytic leukemia or small lymphocytic lymphoma. About 630 participants will be randomly assigned to receive either the new combination or a standard trea…

This study compares a new drug, nemtabrutinib, with two standard treatments (ibrutinib or acalabrutinib) in people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. About 1,200 participants will be randomly assigned to receive either nemtabrutinib or the …

This study tests three different doses of an experimental drug called pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer came back or didn't respond to a previous type of targeted therapy (a BTK inhibitor). The goal is…

This study is for people newly diagnosed with high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who do not yet have symptoms. It compares starting treatment early with two drugs (venetoclax and obinutuzumab) versus waiting to treat until symptoms ap…

This early-stage study is for people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to standard treatments. Researchers are testing a drug called mosunetuzumab, either alone or combined with another drug (venetoclax), to see if they are safe and …

This study tests a new drug, BGB-16673, against another drug, pirtobrutinib, in people whose chronic lymphocytic leukemia or small lymphocytic lymphoma has returned or stopped responding to prior treatment. About 500 participants will receive one of the two drugs to see which wor…

This study tests a drug called polatuzumab vedotin combined with standard chemotherapy for people whose chronic lymphocytic leukemia has turned into a more aggressive form called Richter's transformation. About 20 adults will receive up to six treatment cycles and be monitored fo…

This study is testing whether a combination of three drugs—pirtobrutinib, venetoclax, and obinutuzumab—can help control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after previous treatment. The treatment is given for a limited time, n…

This study tests whether adding venetoclax to ongoing ibrutinib or acalabrutinib treatment can clear remaining leukemia cells in people with high-risk chronic lymphocytic leukemia (CLL). About 90 participants who have been on ibrutinib or acalabrutinib for at least a year will re…

This study checks the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia or non-Hodgkin lymphoma. Participants must have already finished a Lilly-sponsored pirtobrutinib study. The goal is to monitor side effects and overall survival over time.

This phase 3 study compares a new drug, pirtobrutinib, to the standard drug ibrutinib in people with chronic lymphocytic leukemia or small lymphocytic lymphoma. About 662 participants, who may or may not have had prior treatment, will receive one of the two drugs. The goal is to …

This study tests an experimental drug, BGB-16673, designed to destroy a protein that helps certain blood cancers grow. It is for people with B-cell cancers like lymphoma or leukemia that have come back or not responded to other treatments. The trial has two parts: first finding a…

This study tests a drug called glofitamab, alone or with other medicines, in people whose chronic lymphocytic leukemia has turned into a more aggressive lymphoma (Richter's transformation). About 70 adults will receive treatment to see if the cancer shrinks or disappears. The goa…

This study compares a new drug pair (sonrotoclax plus zanubrutinib) to a standard pair (venetoclax plus acalabrutinib) in 500 adults with untreated chronic lymphocytic leukemia (CLL). The goal is to see which combination better delays disease progression and clears cancer cells f…

This study is for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already taking a BTKi pill (like ibrutinib). It compares staying on the BTKi pill alone versus adding a second pill, venetoclax, for one year and then stopping both. The g…

This study tests a mix of three drugs (venetoclax, obinutuzumab, and possibly acalabrutinib) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatment. The approach is personalized: treatment is a…

This study tests two drugs together for people with Richter transformation, a fast-growing lymphoma that can arise from chronic lymphocytic leukemia. The drugs aim to block cancer growth and help the immune system attack the cancer. About 32 adults who have not responded to or ca…

This early-stage trial tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to standard treatments. The study aims to find the safest dose and see if the therapy can control the cancer. Abo…

This study tests whether taking the targeted therapy venetoclax in cycles (on and off) works as well as taking it every day, when combined with another drug, acalabrutinib, in people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).…

This study tests whether adding a newer drug, epcoritamab, to a standard two-drug combination can make cancer disappear more completely and for longer in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 33 adults who have not had…

This study tests whether giving two drugs (acalabrutinib and obinutuzumab) in cycles can control chronic lymphocytic leukemia (CLL) and allow patients to stop treatment for a while. About 60 adults with untreated CLL who need therapy will participate. The goal is to see if this a…

This study tests a new daily pill, LP-118, in up to 100 people with blood cancers that have come back or not responded to treatment. The main goal is to find the safest dose and see how the drug works in the body. Early results will also hint at whether it can shrink tumors or sl…

This early-phase study tests a combination of three drugs (tafasitamab, acalabrutinib, and obinutuzumab) in people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to check safety and see how well the drugs work togethe…

This phase 2 study tests whether adding the experimental drug emavusertib to an approved targeted therapy (zanubrutinib) can improve outcomes for adults with chronic lymphocytic leukemia (CLL) and related B-cell cancers. About 108 participants will receive the combination to see …

This early-stage study tests an experimental drug called ABBV-319 in adults with B-cell cancers (lymphomas and leukemia) that have come back or not responded to treatment. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 154 parti…

This study offers ongoing access to the drug ibrutinib for up to 700 people with certain blood cancers (like chronic lymphocytic leukemia or mantle cell lymphoma) who are already taking it and benefiting. The goal is to track long-term safety and see how well the drug controls th…

This early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia). The main goals are to check safety, find the best dose, and see how the body handles the drug. Participants must have a confirmed diagnosis and be …

This early-stage trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV), a common and dangerous infection after transplant. About 46 people with various blood cancers or disorders will take part. The g…

This study tests whether giving yearly pneumococcal vaccines to people with chronic lymphocytic leukemia (CLL) offers better protection than the current standard of revaccination every 5 years. About 80 untreated CLL patients will receive either the yearly schedule or the standar…

This study tests a vaccine (CMV-MVA Triplex) given to stem cell donors to help prevent CMV infection in patients receiving a stem cell transplant. The vaccine boosts the donor's immunity against CMV, which is then passed to the patient through the transplant. About 216 donor-reci…

This study collects blood, bone marrow, or lymph node samples from 60 people with chronic lymphocytic leukemia (CLL) who are taking or about to take BTK degraders. Researchers will analyze the samples to find out why some patients stop responding to these drugs. The goal is to be…

This study tracks 50 adults with chronic lymphocytic leukemia (CLL) who are starting acalabrutinib alone (no other cancer drugs). Researchers will watch how long patients stay on the drug and why they might stop, aiming to fill a gap in real-world data. No new treatment is tested…

This study collects blood and tissue samples from 2000 people—some with cancer, some without—to help researchers develop and improve blood tests that can detect many types of cancer early. Participants provide samples that are stored and later used to test new diagnostic methods.…

This study follows 2000 people with chronic lymphocytic leukemia (CLL) who received their first treatment in earlier clinical trials. Researchers want to see how long patients live and what factors affect their survival over time. No new treatments are given; this is an observati…

This study follows up to 500 people who received CAR-T cell therapy for blood cancers like leukemia, lymphoma, or multiple myeloma. Researchers will track participants for up to 15 years to see if any new cancers develop. The goal is to understand the long-term safety of this tre…

This study collects blood and tissue samples along with medical information from up to 2750 people with chronic lymphocytic leukemia (CLL) or related conditions. Researchers hope to learn more about what causes CLL and how it behaves. Participants provide samples during routine c…

This study looks at how chronic lymphocytic leukemia (CLL) cells use nutrients like glucose and glutamine compared to normal cells. Researchers will give participants a special drink with harmless tracers and then measure how the cancer cells process these nutrients. The goal is …

This study looks at how chronic lymphocytic leukemia (CLL) and a related condition called monoclonal B-cell lymphocytosis (MBL) affect bone marrow function, especially the ability to fight infections. Researchers will compare samples from 50 participants, including people with CL…

This study looks at the costs and benefits of starting treatment early versus waiting in people with high-risk chronic lymphocytic leukemia (CLL) who have no symptoms. Researchers will track medical visits, tests, and hospital stays over 10 years to see which approach gives bette…

This study gathers basic survival and complication information from 2000 people receiving stem cell transplants for blood cancers or immune diseases. The goal is to build a database for future research and to improve patient care. No new treatments are being tested; only standard…

This study measures how people with chronic lymphocytic leukemia (CLL) feel and function while taking the drug acalabrutinib. Researchers will look at quality-of-life questionnaires filled out by 120 patients in France over 12 months. The goal is to understand real-world experien…

This study looks at how the flu and COVID vaccines affect the immune system in people with different types of lymphoma. Researchers will measure antibody levels and immune cells over time, comparing them to people without lymphoma. The goal is to better understand how lymphoma an…

This study looks at genetic changes in chronic lymphocytic leukemia (CLL) patients during treatment with the drug venetoclax. Researchers want to understand how the drug affects cancer cells and the immune system. The study involves 75 adults with relapsed or refractory CLL who w…

This study is for people starting a type of blood cancer medication called BTK inhibitors. Researchers want to see if a small heart monitor (implanted under the skin) can detect irregular heartbeats that these drugs might cause. The goal is to catch problems early and guide treat…

This study looks at whether CAR-T cell therapy reduces the protection that vaccines (like measles, mumps, and rubella) provide in people with multiple myeloma and non-Hodgkin lymphoma. Researchers will measure antibody levels before and after CAR-T treatment in 45 adults. The goa…